Concepedia

Lahar Mehta

LM

Statistics

Publications

21

Citations

1.5K

H-Index

18

Active since

2006

Affiliations

Lundbeck (United States)(Current)

Biogen (United States)

Lundbeck (Denmark)

La Jolla Alcohol Research

Seagen (United States)

Lahar Mehta is an author at Lundbeck (United States) specializing in neurology, pharmacotherapy, and pharmacy.

Publications per year

2006–2023

21

Publications

21

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial

Jacob Elkins, Roland Veltkamp, Joan Montaner et al. · The Lancet Neurology · 2017 · 214 citations

, , +11

Five years of ocrelizumab in relapsing multiple sclerosis

Stephen L. Hauser, Ludwig Kappos, Douglas L. Arnold et al. · Neurology · 2020 · 158 citations · Full text

, , +14

The syndrome of delayed post-hypoxic leukoencephalopathy

David Shprecher, Lahar Mehta · Neurorehabilitation · 2010 · 133 citations

, , +7

Cost-effectiveness of disease-modifying therapy for multiple sclerosis

Katia Noyes, Alina Bajorska, A T Chappel et al. · Neurology · 2011 · 107 citations · Full text

, , +13

The syndrome of delayed post-hypoxic leukoencephalopathy.

David Shprecher, Lahar Mehta · PubMed · 2010 · 106 citations

, , +16

1–5 of 21